As a prominent player in the pharmaceuticals industry, Eli Lilly continues to demonstrate strong market performance. For detailed analysis including 13 additional ProTips and comprehensive ...

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

The has already reduced its outlook for 2025 (discussed in the next section) owing to the impact ... treatments market faces a big challenge as chief rival Eli Lilly's (LLY) Zepbound is catching ...

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Are you looking to make informed trading decisions and stay ahead of the crowd operating in the forex market ... impact the relative value of the currency it issues. In particular, fundamental ...

The move marks another escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound is in a head-to-head contest with the latter's Wegovy ...

Still, with more questions about their impact on the body asked every day, more in-depth analysis is being done ... trial comparing its weight-loss drug Zepbound to its main rival Wegovy from ...